期刊文献+

高效液相色谱法测定马拉韦罗片的含量

Determination of maraviroc tablets by high performance liquid chromatography
原文传递
导出
摘要 目的建立高效液相色谱法测定马拉韦罗片的含量。方法色谱柱:Shimadzu C18柱(250 mm×4.6 mm,5μm),流动相:乙腈-0.01 mol.L-1磷酸二氢钾溶液(25∶75,V/V),柱温:(35.0±1.0)℃,流速:1.0 mL.min-1,检测波长:197 nm。结果马拉韦罗的线性范围为0.1~0.5 g.L-1(r=0.999 7),平均回收率为(99.83±0.60)%(n=9)。结论本方法简便、准确,可用于马拉韦罗片的含量测定。 AIM To establish a method for content determination of maraviroc tablets by high performance liquid chromatography.METHODS A Shimadzu C18 column(250 mm × 4.6 mm,5 μm)was used with the mobile phase of acetonitrile-0.01 mol·L-1 potassium dihydrogen orthophosphate solution(25:75,V/V).Column temperature was(35.0 ± 1.0)℃.Flow rate was 1.0 mL·min-1.UV detection wave length was 197 nm.RESULTS The linear range of maraviroc tablets was 0.1-0.5 g·L-1(r = 0.999 7),with average recovery was(99.83 ± 0.60)%(n = 9).CONCLUSION The established method is simple,accurate and suitable for the quality control of maraviroc tablets.
作者 张霞
出处 《中国新药与临床杂志》 CAS CSCD 北大核心 2012年第2期110-112,共3页 Chinese Journal of New Drugs and Clinical Remedies
关键词 马拉韦罗 含量 色谱法 高压液相 maraviroc content chromatography high pressure liquid
  • 相关文献

参考文献4

  • 1王珍燕,卢洪洲.抗HIV新药--CCR5拮抗剂马拉韦罗[J].中国艾滋病性病,2008,14(4):431-434. 被引量:3
  • 2封宇飞,傅得兴.CCR5阻滞剂马拉韦罗的药理与临床评价[J].中国新药杂志,2008,17(17):1544-1547. 被引量:1
  • 3NOTARI S,TOMMASI C,NICASTRI E,et al.Simultaneousdetermination of maraviroc and raltegravir in human plasma byHPLC-UV[J].IUBMB Life,2009,61(4):470-475.
  • 4PATRICK DORR,MIKE WESTBY,SUSAN DOBBS,et al.Maraviroc(UK-427,857),a potent,orally bioavailable,andselective small-molecule inhibitor of chemokine receptor CCR5with broad-spectrum anti-human immunodeficiency virus type 1activity[J].Antimicrob Agents and Chemother,2005,49(11):4721-4732.

二级参考文献20

  • 1FDA approves maraviroc tablets [ J ]. AIDS Patient Care STDS, 2007,21 (9) :702.
  • 2Selzentr[ EB/OL ]. ( 2007 - 12 - 04 ). http://www. fda. gov/ cder/foi/label/2007/022128 lbl. pdf.
  • 3BARRETINA GINESTA J, CASTANER J, BOZZO J, et al. Maraviroc, anti-HIV agent viral enter inhibitor chemokine CCR5 antagonist [ J ]. Drugs Future, 2005,30 ( 5 ) : 469 - 477.
  • 4MEANWELL NA, KADOW JF. Maraviroc, a chemokine CCR5 receptor antagonist for the treatment of HIV infection and AIDS [ J ]. Curr Opin Investig Drugs, 2007,8 (8) :669 - 681.
  • 5WALKER DK, ABEL S, COMBY P,et al. Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV [ J ]. Drug Metab Dispos, 2005, 33 (4) : 587 -595.
  • 6More data on maraviroc in treatment-experienced patients[ J ]. IDS Patient Care STDS, 2007,21 ( 5 ) : 366 - 367.
  • 7FATKENHEUER G, POZNIAK AL, JOHNSON MA, et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1 [J]. Nat Med, 2005,11 (11) :1170 -1172.
  • 8ROSARIO MC, POLAND B, SULLIVAN J, et al. A pharmacokinetic-pharmacodynamic model to optimize the phase Ⅱa development program of maraviroc [ J]. J Acquir Immune Defic Syndr, 2006,42(2) :183 - 191.
  • 9O' Brien SJ, Moore JP.The effect of genetic vaiation in chemokines and their receptors on HIV transmission and progression to AIDS[J].Immunol Rev,2000,177:99 - 111.
  • 10Dorr P,Westby M,Dobbs S,et al. Maraviroc(UK-427,857),a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity [ J ] .Antimicrob Agents Chemother, 2005,49( 11 ) : 4721 - 4732.

共引文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部